Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Metastatic melanoma (MM) has a poor prognosis and is resistant to standard treatments.
• There is a critical need for novel therapeutic strategies to improve MM patient outcomes.
• Anti-angiogenic therapies, including monoclonal antibodies and kinase inhibitors, represent an innovative approach in cancer drug development.

Purpose of the Study:

• To review current concepts and controversies regarding angiogenesis and anti-angiogenic therapies in MM.
• To discuss the role of angiogenesis in melanoma progression and identify potential therapeutic targets.
• To examine the efficacy of anti-angiogenic strategies in preclinical and clinical settings and consider future directions.

Main Methods:

• Literature review of preclinical and clinical studies on angiogenesis and anti-angiogenic therapies in melanoma.
• Analysis of key molecular targets involved in melanoma angiogenesis.
• Discussion of current controversies and future perspectives in the field.

Main Results:

• Angiogenesis plays a crucial role in melanoma progression.
• Several molecular targets for anti-angiogenic therapy have been identified.
• Preclinical and clinical data suggest potential efficacy for anti-angiogenic strategies in MM, though challenges remain.

Conclusions:

• Anti-angiogenic therapies hold promise as a novel treatment modality for metastatic melanoma.
• Further research is needed to optimize anti-angiogenic strategies and overcome resistance mechanisms in MM.
• Understanding angiogenesis in melanoma may inform future therapeutic developments and improve patient management.